Lista de obras -

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

artículo científico publicado en 2016

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

artículo científico publicado en 2017

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

scientific article published on 03 November 2020

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

artículo científico publicado en 2020

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

artículo científico publicado en 2016

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

scientific article published on 23 August 2020

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

artículo científico publicado en 2018

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

artículo científico publicado en 2018

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens

artículo científico publicado en 2016

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

artículo científico publicado en 2010

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

artículo científico publicado en 2015

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

artículo científico publicado en 2019

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens

artículo científico publicado en 2011

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

artículo científico publicado en 2017

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

artículo científico publicado en 2020

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

artículo científico publicado en 2007

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

artículo científico publicado en 2010

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

artículo científico publicado en 2020

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

artículo científico publicado en 2007

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

artículo científico publicado en 2008

Lista de obras de

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens